Haemodynamics, fluids & transfusion

Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock

N Engl J MedPublished Randomised controlled trial

Primary result · Major adverse kidney eventResult — go to the resultAdjusted difference 1.2 percentage points 95% CI −7.1 to 9.4

Authors' conclusion

The use of sodium bicarbonate in critically ill patients with metabolic acidosis receiving vasopressors did not lead to a lower risk of major adverse kidney events within 30 days than placebo.

Study context

Population
Adults in the intensive care unit (ICU) receiving vasopressors with metabolic acidosis (pH <7.30; base excess ≤−4 mmol/L; PaCO2 ≤45 mm Hg without intubation or ≤50 mm Hg with intubation)
Participants
500 adults · 55 ICUs · 7 countries
Comparison
Sodium bicarbonate vs Placebo
  • Sodium bicarbonaten = 245
  • Placebon = 255reference
Primary endpoint
Major adverse kidney event:
  • Death
  • RRT
  • Persistent renal dysfunction
Follow-up
30 days
Methodological detailspragmatic, adaptive, double-blind, placebo-controlled, multicentre
  • Pragmatic
  • Adaptive
  • Double-blind
  • Placebo-controlled
  • Multicentre

Primary result

Major adverse kidney event

Adjusted difference

1.2 percentage points

95% CI −7.1 to 9.4

P = 0.78

Events by treatment group

Sodium bicarbonate vs Placebo
adjusted difference 1.2 percentage points (95% CI −7.1 to 9.4); P = 0.78

As reported in the abstract

Further findings

OutcomeSodium bicarbonatePlaceboAdjusted difference (percentage points) (95% CI)
RRT use · 30 days16.8%20.9%−3.9 (−10.6 to 2.7)
In-hospital mortality · day 3025.4%24.0%1.8 (−5.6 to 9.2)

Safety

OutcomeSodium bicarbonatePlaceboP value
Adverse effect1.6%0 eventsP = 0.06

Original publication

Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock. N Engl J Med. Published 12 June 2026. doi:10.1056/nejmoa2600526

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.